Recaticimab
Recaticimab (SHR-1209) is an orally active humanized monoclonal IgG1 antibody targeting PCSK9. Recaticimab binds PCSK9 with high affinity, increases the level of low density lipoprotein receptor on the surface of liver cells, and decreases the level of low density lipoprotein cholesterol in plasma. Recaticimab can be used in the study of hypercholesterolemia and hyperlipidemia[1][2].
Product Specifications
CAS Number
2361290-85-7
Product Name Alternative
SHR-1209
UNSPSC
12352203
Target
LDLR; PCSK9
Type
Inhibitory Antibodies
Related Pathways
Metabolic Enzyme/Protease
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/recaticimab.html
Purity
99.71
Solubility
10 mM in DMSO
Smiles
[Recaticimab]
Molecular Weight
(148.42 kDa)
References & Citations
[1]Xu M, et al. PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 study. BMC Med. 2022 Jan 18;20 (1) :13. |[2]Gupta K, et al. Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 European Society of Cardiology Congress. Curr Atheroscler Rep. 2023 Dec;25 (12) :965-978.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 4
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
![MALT1 Mouse Monoclonal Antibody (HRP conjugated) [Clone ID: OTI4C3]](https://cdn.genprice.uk/products/937/6868c3d8994c49e6dc40026d/imageurl/ta807326bm.webp)
TA807326BM 100 µL
MALT1 Mouse Monoclonal Antibody (HRP conjugated) [Clone ID: OTI4C3]
Sign In for Pricing
View Details 
